Zylox-Tonbridge Medical Technology Co., Ltd. (ZYLOXTB) disclosed a share repurchase on 27 March 2026, acquiring 150,000 H-shares on the Hong Kong Stock Exchange.

• Transaction details – Trading date: 27 March 2026 – Method: On-market repurchase – Price range: HKD 23.66 – HKD 24.10 per share – Volume-weighted average price: HKD 23.92 per share – Aggregate consideration: HKD 3.59 million

• Impact on share capital – Issued shares (excluding treasury shares) declined from 329.05 million to 328.90 million, a 0.04% reduction. – Treasury shares increased from 7.30 million to 7.45 million. – Total issued shares remained unchanged at 336.35 million.

• Repurchase mandate utilisation – Authorised limit (approved 30 May 2025): 31.96 million shares. – Cumulative repurchased to date: 4.64 million shares, equal to 1.42% of the shares outstanding when the mandate was granted. – A 30-day moratorium on new share issues or treasury share disposals applies until 26 April 2026.

The board confirmed that the repurchase complied with all relevant Hong Kong Stock Exchange listing rules and regulatory requirements.